These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 31511612)

  • 21. Sorafenib treatment of FLT3-ITD(+) acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation.
    Man CH; Fung TK; Ho C; Han HH; Chow HC; Ma AC; Choi WW; Lok S; Cheung AM; Eaves C; Kwong YL; Leung AY
    Blood; 2012 May; 119(22):5133-43. PubMed ID: 22368270
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long non-coding RNAs as novel therapeutic targets in juvenile myelomonocytic leukemia.
    Hofmans M; Lammens T; Depreter B; Wu Y; Erlacher M; Caye A; Cavé H; Flotho C; de Haas V; Niemeyer CM; Stary J; Van Nieuwerburgh F; Deforce D; Van Loocke W; Van Vlierberghe P; Philippé J; De Moerloose B
    Sci Rep; 2021 Feb; 11(1):2801. PubMed ID: 33531590
    [TBL] [Abstract][Full Text] [Related]  

  • 23. FLT3-ITD allelic ratio and HLF expression predict FLT3 inhibitor efficacy in adult AML.
    Kivioja J; Malani D; Kumar A; Kontro M; Parsons A; Kallioniemi O; Heckman CA
    Sci Rep; 2021 Dec; 11(1):23565. PubMed ID: 34876631
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of sorafenib on the outcomes of patients with FLT3-ITD acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation.
    Xuan L; Wang Y; Huang F; Jiang E; Deng L; Wu B; Fan Z; Liang X; Xu N; Ye J; Lin R; Yin C; Zhang Y; Sun J; Han M; Huang X; Liu Q
    Cancer; 2018 May; 124(9):1954-1963. PubMed ID: 29509276
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Juvenile myelomonocytic leukaemia-associated mutation in Cbl promotes resistance to apoptosis via the Lyn-PI3K/AKT pathway.
    Bunda S; Qin K; Kommaraju K; Heir P; Ohh M
    Oncogene; 2015 Feb; 34(6):789-97. PubMed ID: 24469048
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sorafenib induces paradoxical phosphorylation of the extracellular signal-regulated kinase pathway in acute myeloid leukemia cells lacking FLT3-ITD mutation.
    Fouladi F; Jehn LB; Metzelder SK; Hub F; Henkenius K; Burchert A; Brendel C; Stiewe T; Neubauer A
    Leuk Lymphoma; 2015; 56(9):2690-8. PubMed ID: 25665465
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Crenolanib is active against models of drug-resistant FLT3-ITD-positive acute myeloid leukemia.
    Zimmerman EI; Turner DC; Buaboonnam J; Hu S; Orwick S; Roberts MS; Janke LJ; Ramachandran A; Stewart CF; Inaba H; Baker SD
    Blood; 2013 Nov; 122(22):3607-15. PubMed ID: 24046014
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The ability of sorafenib to inhibit oncogenic PDGFRbeta and FLT3 mutants and overcome resistance to other small molecule inhibitors.
    Lierman E; Lahortiga I; Van Miegroet H; Mentens N; Marynen P; Cools J
    Haematologica; 2007 Jan; 92(1):27-34. PubMed ID: 17229632
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Metabolic reprogramming and redox adaptation in sorafenib-resistant leukemia cells: detected by untargeted metabolomics and stable isotope tracing analysis.
    You X; Jiang W; Lu W; Zhang H; Yu T; Tian J; Wen S; Garcia-Manero G; Huang P; Hu Y
    Cancer Commun (Lond); 2019 Apr; 39(1):17. PubMed ID: 30947742
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Response of ETV6-FLT3-positive myeloid/lymphoid neoplasm with eosinophilia to inhibitors of FMS-like tyrosine kinase 3.
    Walz C; Erben P; Ritter M; Bloor A; Metzgeroth G; Telford N; Haferlach C; Haferlach T; Gesk S; Score J; Hofmann WK; Hochhaus A; Cross NC; Reiter A
    Blood; 2011 Aug; 118(8):2239-42. PubMed ID: 21705501
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Investigational FMS-like tyrosine kinase 3 inhibitors in treatment of acute myeloid leukemia.
    Pemmaraju N; Kantarjian H; Andreeff M; Cortes J; Ravandi F
    Expert Opin Investig Drugs; 2014 Jul; 23(7):943-54. PubMed ID: 24749672
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bi-allelic mutations of CCDC88C are a rare cause of severe congenital hydrocephalus.
    Ruggeri G; Timms AE; Cheng C; Weiss A; Kollros P; Chapman T; Tully H; Mirzaa GM
    Am J Med Genet A; 2018 Mar; 176(3):676-681. PubMed ID: 29341397
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and Feasibility of Sorafenib as a Maintenance Agent After Allogeneic Hematopoietic Stem Cell Transplantation for Fms-like Tyrosine Kinase 3 Mutated Acute Myeloid Leukemia: An Update.
    Battipaglia G; Massoud R; Ahmed SO; Legrand O; El Cheikh J; Youniss R; Aljurf M; Mohty M; Bazarbachi A
    Clin Lymphoma Myeloma Leuk; 2019 Aug; 19(8):506-508. PubMed ID: 31122828
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Haematopoietic cell transplantation with and without sorafenib maintenance for patients with FLT3-ITD acute myeloid leukaemia in first complete remission.
    Brunner AM; Li S; Fathi AT; Wadleigh M; Ho VT; Collier K; Connolly C; Ballen KK; Cutler CS; Dey BR; El-Jawahri A; Nikiforow S; McAfee SL; Koreth J; Deangelo DJ; Alyea EP; Antin JH; Spitzer TR; Stone RM; Soiffer RJ; Chen YB
    Br J Haematol; 2016 Nov; 175(3):496-504. PubMed ID: 27434660
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety of FLT3 inhibitors in patients with acute myeloid leukemia.
    Cerchione C; Peleteiro Raíndo A; Mosquera Orgueira A; Mosquera Torre A; Bao Pérez L; Marconi G; Isidori A; Pérez Encinas MM; Martinelli G
    Expert Rev Hematol; 2021 Sep; 14(9):851-865. PubMed ID: 34424108
    [No Abstract]   [Full Text] [Related]  

  • 36. Juvenile myelomonocytic leukemia with PTPN11 mutation in a 23-month-old girl.
    Jakovljević G; Kardum-Skelin I; Rogosić S; Nakić M
    Coll Antropol; 2010 Mar; 34(1):251-4. PubMed ID: 20432758
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Aberrant activation of the PI3K/mTOR pathway promotes resistance to sorafenib in AML.
    Lindblad O; Cordero E; Puissant A; Macaulay L; Ramos A; Kabir NN; Sun J; Vallon-Christersson J; Haraldsson K; Hemann MT; Borg Å; Levander F; Stegmaier K; Pietras K; Rönnstrand L; Kazi JU
    Oncogene; 2016 Sep; 35(39):5119-31. PubMed ID: 26999641
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunophenotyping with CD135 and CD117 predicts the FLT3, IL-7R and TLX3 gene mutations in childhood T-cell acute leukemia.
    Noronha EP; Andrade FG; Zampier C; de Andrade CF; Terra-Granado E; Pombo-de-Oliveira MS;
    Blood Cells Mol Dis; 2016 Mar; 57():74-80. PubMed ID: 26852660
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Patterns of molecular response to and relapse after combination of sorafenib, idarubicin, and cytarabine in patients with FLT3 mutant acute myeloid leukemia.
    Al-Kali A; Cortes J; Faderl S; Jones D; Abril C; Pierce S; Brandt M; Kantarjian H; Ravandi F
    Clin Lymphoma Myeloma Leuk; 2011 Aug; 11(4):361-6. PubMed ID: 21816375
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Metformin synergistically sensitizes FLT3-ITD-positive acute myeloid leukemia to sorafenib by promoting mTOR-mediated apoptosis and autophagy.
    Wang F; Liu Z; Zeng J; Zhu H; Li J; Cheng X; Jiang T; Zhang L; Zhang C; Chen T; Liu T; Jia Y
    Leuk Res; 2015 Dec; 39(12):1421-7. PubMed ID: 26505133
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.